78. Hypopituitarism Clinical trials / Disease details
Clinical trials : 494 / Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04897802 (ClinicalTrials.gov) | September 13, 2021 | 17/5/2021 | Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) | Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study) | Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolation;Hypothalamic Diseases;Pituitary Diseases;Oxytocin Deficiency | Drug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administration | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Instituto de Salud Carlos III | Recruiting | 18 Years | 65 Years | All | 52 | Phase 4 | Spain |
| 2 | EUCTR2020-004115-27-ES (EUCTR) | 10/05/2021 | 01/09/2021 | Identification and clinical relevance of oxytocin deficient status: GLP1 study | Identification and clinical relevance of oxytocin deficient status: randomized, crossover, placebo-controlled pathophysiological pilot study: GLP1 study | Hypopituitarism;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Byetta INN or Proposed INN: EXENATIDE | Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 52 | Phase 2 | Spain |